PTAB Axes Bulk Of Possible Cancer Treatment Patent In PGR
Law360 (March 20, 2020, 4:47 PM EDT) — The Patent Trial and Appeal Board has invalidated the overwhelming majority of claims Hybrigenics SA challenged in a Forma Therapeutics Inc. patent for a potential cancer treatment for lack of written description support, while at the same time upholding a single claim.
The board’s decision, which was issued Thursday, came in a post-grant review of the patent, which relates to inhibitors of the enzyme ubiquitin-specific protease 7, which the patent says “has the potential to be a treatment for cancers and other disorders.”
Click here to read this article in its entirety.
Contact
Before sending, please note:
Information on www.stites.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.
Before sending, please note:
Information on www.stites.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.
Before sending, please note:
Information on www.stites.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.
Related Capabilities